Web Results
Find Health Information on Healthline
Find Info About:
Healthline is the leading provider of health information.

www.cell.com/cell/references/S0092-8674(16)30851-0

Jul 21, 2016 ... Ledgerwood et al., 2013Ledgerwood, J.E., Zephir, K., Hu, Z., Wei, C.J., Chang, L., Enama, M.E., Hendel, C.S., Sitar, S., Bailer, R.T., Koup, R.A...., and VRC 310 Study Team. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4978566

Jul 21, 2016 ... In terms of reproducibility, the HV1-69-derived antibodies have the additional advantage of utilizing heavy chain-only recognition, and prior studies have shown their vaccine-induced elicitation (Khurana et al., 2013; Ledgerwood et al., 2011; Ledgerwood et al., 2013; Sui et al., 2009; Wheatley et al., 2015; ...

www.ncbi.nlm.nih.gov/pubmed/27453470

Jul 21, 2016 ... Joyce MG(1), Wheatley AK(1), Thomas PV(1), Chuang GY(1), Soto C(1), Bailer RT(1), Druz A(1), Georgiev IS(2), Gillespie RA(1), Kanekiyo M(1), Kong ... Baxa U (5); NISC Comparative Sequencing Program(6), Mullikin JC(6), Subbarao K(4), Douek DC(1), Graham BS(1), Koup RA(1), Ledgerwood JE(1), ...

www.who.int/entity/immunization/research/meetings_workshops/PDVAC_2017_rNucleic_Acid_Vaccines_Graham.pdf

Dec 12, 2016 ... Nucleic Acid Vaccines – DNA vs. mRNA. Lymph node ... Ledgerwood JE, et al. the VRC 306 and 310 Study. Teams. Lancet Infect Dis. ... Ledgerwood et al. J Infect Dis. 2011;203:1396-1404. Ab (EC50) by RVP neutralization assay responses. A West Nile Virus DNA Vaccine Utilizing a. Modified Promoter ...

www.ncbi.nlm.nih.gov/pubmed/19370674

Apr 15, 2009 ... Interventions for preventing falls in older people living in the community. Gillespie LD(1), Robertson MC, Gillespie WJ, Lamb SE, Gates S, Cumming RG, Rowe BH. Author information: (1)Department of Medical and Surgical Sciences, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, ...

www.tandfonline.com/doi/full/10.1080/21645515.2017.1306615

ABSTRACT. The author reviews the foundation of the Coalition for Epidemic Preparedness and Innovations and the choices it has made for funding of vaccine development against epidemic diseases. He comments on those decisions as well as proposing how CEPI could remain relevant for the long term. KEYWORDS: ...

www.marshall.usc.edu/sites/default/files/wakslak/intellcont/Ledgerwood_Wakslak__Wang_in_press_JESP-1.pdf

Feb 27, 2010 ... 85% (in Study 1a) to either 65% vs. 85% or 60% vs. 90% in this study. Disparity size did not moderate our results; the reported analyses therefore collapse across version. 2. A. Ledgerwood et al. / Journal of Experimental Social Psychology xxx (2010) xxx–xxx. ARTICLE IN PRESS. Please cite this article in ...

www.fredhutch.org/en/labs/vaccine-and-infectious-disease/publications.html

Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV- infected children in Kenya (PUSH): a randomised controlled trial. Lancet HIV. 2018 Jan;5(1):e12-e22. Full-text Article: ... Prentice RL, Huang Y, Neuhouser ML, Tinker LF, Van Horn L. Prentice et al. Respond to "Improving Estimation of Sodium Intake" ...

researchonline.lshtm.ac.uk/638999/1/CD000567.pdf

Mar 16, 2012 ... The pooled RR was 1.10 (95% CI 1.02 to 1.19). Modified gelatin - 11 trials compared modified gelatin with crystalloid and included 506 patients. The pooled RR was 0.91 (95% CI 0.49 to 1.72). (When the trials by. Boldt et al were removed from the three preceding analyses, the results were unchanged.) ...